Incyte Corporation has announced an extension in the regulatory review process by the U.S. Food and Drug Administration (FDA) for its supplemental New Drug Application (sNDA) for ruxolitinib cream (Opzelura®). This topical Janus kinase (JAK) inhibitor is intended for the treatment of children aged 2-11 with mild to moderate atopic dermatitis. The Prescription Drug User Fee Act (PDUFA) action date has now been extended by three months to September 19, 2025. This extension allows the FDA additional time to review newly submitted chemistry, manufacturing, and controls data related to the 0.75% strength cream. The sNDA is supported by data from the Phase 3 TRuE-AD3 study, which demonstrated significant efficacy and a consistent safety profile for ruxolitinib cream in the pediatric population.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。